Citations

Clear

246 citation(s) found for "Study, Alfa".

The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease
Rosenberg, Paul B. , Leoutsakos, Jeannie‐Marie , Lyketsos, Constantine G. , Rabins, Peter V., Zandi, Peter P. , Breitner, John C.S. , Norton, Maria C. , Zuckerman, Ilene H., Rattinger, Gail B. , Green, R. C., Tschanz, JoAnn T. , Mielke, Michelle M. , Han, Dan , Welsh-Bohmer, Kathleen Anne , Corcoran, Cheryl Mary

Mayo Clinic

International Journal of Geriatric Psychiatry | February 29, 2012 | Volume: 27 | Issue: 12 | Pages: 1248-1257

10.1002/gps.3769 | PMID 22374884 Get It

ObjectiveThe use of psychotropic medications in Alzheimer's disease (AD) has been associated with both deleterious and potentially beneficial outcomes. We examined the longitudinal association of psychotropic medication use with cognitive, functional, and neuropsychiatric symptom (NPS) trajectories among community‐ascertained incident AD cases from the Cache County Dementia Progression Study.MethodsA total of 230 participants were followed for a mean of 3.7 years. Persistency index (PI) was calculated for all antidepressants, selective serotonin reuptake inhibitors (SSRIs), antipsychotics (atypical and typical), and benzodiazepines as the proportion of observed time of medication exposure. Mixed‐effects models were used to examine the association between PI for each medication class and Mini‐Mental State Exam (MMSE), Clinical Dementia Rating Sum of Boxes (CDR‐Sum), and Neuropsychiatric Inventory – Total (NPI‐Total) trajectories, controlling for appropriate demographic and clinical covariates.ResultsAt baseline, psychotropic medication use was associated with greater severity of dementia and poorer medical status. Higher PI for all medication classes was associated with a more rapid decline in MMSE. For antidepressant, SSRI, benzodiazepine, and typical antipsychotic use, a higher PI was associated with a more rapid increase in CDR‐Sum. For SSRIs, antipsychotics, and typical antipsychotics, a higher PI was associated with more rapid increase in NPI‐Total.ConclusionsPsychotropic medication use was associated with more rapid cognitive and functional decline in AD, and not with improved NPS. Clinicians may tend to prescribe psychotropic medications to AD patients at risk of poorer outcomes, but one cannot rule out the possibility of poorer outcomes being caused by psychotropic medications. Copyright © 2012 John Wiley & Sons, Ltd.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Phelps, Creighton H., Beach, Thomas G. , Bigio, Eileen H. , Cairns, Nigel J. , Carrillo, María C. , Dickson, Dennis W. , Duyckaerts, Charles , Frosch, Matthew P. , Masliah, Eliezer , Mirra, Suzanne S., Nelson, Peter T. , Thal, Dietmar Rudolf , Thies, Bill, Trojanowski, John Q. , Vinters, Harry V. , Montine, Thomas J. , Hyman, Bradley T. , Schneider, Julie A. , Dickson, Dennis W , Thal, Dietmar Rudolf

Mayo Clinic

Alzheimer's & Dementia | January 19, 2012 | Volume: 8 | Issue: 1 | Pages: 1-13

10.1016/j.jalz.2011.10.007 | PMID 22265587 Get It

Abstract A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
A yeast functional screen predicts new candidate ALS disease genes
Couthouis, Julien , Hart, Michael P. , Shorter, James , DeJesus‐Hernandez, Mariely, Erion, Renske, Oristano, Rachel, Liu, Annie X., Ramos, Daniel M. , Jethava, Niti, Hosangadi, Divya, Epstein, James, Chiang, Ashley, Diaz, Zamia, Nakaya, Tadashi , Ibrahim, Fadia , Kim, Hyung‐Jun , Solski, Jennifer A., Williams, Kelly L. , Mojsilovic‐Petrovic, Jelena , Ingre, Caroline , Graff‐Radford, Neill R. , Dickson, Dennis W. , Clay-Falcone, Dana, Elman, Lauren , McCluskey, Leo, Greene, Robert A., Kalb, Robert G. , Trojanowski, John Q. , Ludolph, Albert C. , Robberecht, Wim, Nicholson, Garth A. , Blair, Ian P. , King, Oliver D. , Rademakers, Rosa , Mourelatos, Zissimos P. , Gitler, Aaron D. , Fifita, Jennifer A. , Epstein, James, Boylan, Khrista , Lee, Virginia M.‐Y. , Andersen, Peter Munch , Bonini, Nancy M. , Deerlin, Vivianna M. Van , Dickson, Dennis W , Gitler, Aaron D , Shorter, James

Mayo Clinic

Proceedings of the National Academy of Sciences | November 8, 2011 | Volume: 108 | Issue: 52 | Pages: 20881-20890

10.1073/pnas.1109434108 | PMID 22065782 Get It

Amyotrophic lateral sclerosis (ALS) is a devastating and universally fatal neurodegenerative disease. Mutations in two related RNA-binding proteins, TDP-43 and FUS, that harbor prion-like domains, cause some forms of ALS. There are at least 213 human proteins harboring RNA recognition motifs, including FUS and TDP-43, raising the possibility that additional RNA-binding proteins might contribute to ALS pathogenesis. We performed a systematic survey of these proteins to find additional candidates similar to TDP-43 and FUS, followed by bioinformatics to predict prion-like domains in a subset of them. We sequenced one of these genes, TAF15 , in patients with ALS and identified missense variants, which were absent in a large number of healthy controls. These disease-associated variants of TAF15 caused formation of cytoplasmic foci when expressed in primary cultures of spinal cord neurons. Very similar to TDP-43 and FUS, TAF15 aggregated in vitro and conferred neurodegeneration in Drosophila , with the ALS-linked variants having a more severe effect than wild type. Immunohistochemistry of postmortem spinal cord tissue revealed mislocalization of TAF15 in motor neurons of patients with ALS. We propose that aggregation-prone RNA-binding proteins might contribute very broadly to ALS pathogenesis and the genes identified in our yeast functional screen, coupled with prion-like domain prediction analysis, now provide a powerful resource to facilitate ALS disease gene discovery.
P3‐298: Hippocampal volumes are associated with cognitive performance in recently menopausal APOE ∊4 carriers
Tosakulwong, Nirubol , Wharton, Whitney , Gleason, Carey E. , Wille, Samantha, Ward, Chad, Zais, Teresa, Wiste, Heather J. , Weigand, Stephen D. , Asthana, Sanjay , Miller, Virginia , Kantarci, Kejal , Dowling, N. Maritza , Jack, Clifford R. , Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2011.05.1740 Get It

IC‐P‐123: MR elastography of Alzheimer's disease
Murphy, Matthew C. , Felmlee, Joel P. , Glaser, Kevin J. , Huston, John , Jack, Clifford R. , Ehman, Richard L. , Manduca, Armando

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2011.05.088 Get It

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Jack, Clifford R. , Barkhof, Frederik , Bernstein, Matt A. , Cantillon, Marc, Cole, Patricia E., DeCarli, Charles , Dubois, Bruno , Duchesne, Simon , Fox, Nick C. , Frisoni, Giovanni B. , Hampel, Harald , Hill, David , Johnson, Keith A. , Scheltens, Philip , Schwarz, Adam J. , Suhy, Joyce, Thompson, Paul M. , Weiner, Michael W. , Foster, Norman L. , Frisoni, Giovanni B. , Mangin, Jean‐François , Sperling, Reisa Anne , DeCarli, Charles , Bernstein, Matt A , Jack, Clifford R , Thompson, Paul M , Barkhof, Frederik , Scheltens, Philip , Fox, Nick C

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 4 | Pages: 474

10.1016/j.jalz.2011.04.007 | PMID 21784356 Get It

BackgroundThe promise of Alzheimer's disease biomarkers has led to their incorporation in new diagnostic criteria and in therapeutic trials; however, significant barriers exist to widespread use. Chief among these is the lack of internationally accepted standards for quantitative metrics. Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization.Methods and ResultsThe authors of this position paper propose a path toward this goal. The steps include the following: (1) Establish and empower an oversight board to manage and assess the effort, (2) adopt the standardized definition of anatomic hippocampal boundaries on magnetic resonance imaging arising from the European Alzheimer's Disease Centers–Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard, (3) establish a scientifically appropriate, publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects (Alzheimer's Disease Neuroimaging Initiative), and (4) define minimum technical and prognostic performance metrics for validation of new measurement techniques using the reference standard data set as a benchmark.ConclusionsAlthough manual delineation of the hippocampus is the best available reference standard, practical application of hippocampal volumetry will require automated methods. Our intent was to establish a mechanism for credentialing automated software applications to achieve internationally recognized accuracy and prognostic performance standards that lead to the systematic evaluation and then widespread acceptance and use of hippocampal volumetry. The standardization and assay validation process outlined for hippocampal volumetry was envisioned as a template that could be applied to other imaging biomarkers.
Assessment of cognition in early dementia
Silverberg, Nina, Ryan, Laurie, Petersen, Ronald C. , Posner, Holly, Hilsabeck, Robin C. , Rizzo, Albert, Ott, Brian R. , Albert, Marilyn S. , Wagster, Molly V., Schinka, John A., Cullum, C. Munro , Farias, Sarah Tomaszewski , Balota, David A., Budson, Andrew E. , Strutt, Adriana M. , Gollan, Tamar H. , Babcock, Debra, Kramer, Joel H. , Carrillo, María C. , Sperling, Reisa Anne , Snyder, Peter J. , Gallagher, Michela , Raber, Jacob , Possin, Katherine L. , King, Jonathan W. , Kaye, Jeffrey , Rao, Stephen M. , Loewenstein, David , Brandt, Jason , Manly, Jennifer J. , Barnes, Lisa L. , Ganguli, Mary , Litvan, Irene , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 3 | Pages: No page available

10.1016/j.jalz.2011.05.001 | PMID 23559893 Get It

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010
Khachaturian, Zaven S., Petersen, Ronald C., Snyder, Peter J. , Khachaturian, Ara S. , Aisen, Paul , Leon, Mony J. de , Greenberg, Barry , Kukull, Walter A. , Maruff, Paul , Sperling, Reisa A., Stern, Yaakov , Touchon, Jacques, Vellas, Bruno , Andrieu, Sandrine , Weiner, Michael W. , Carrillo, Marı́a C., Bain, Lisa J. , Carrillo, María C. , Stern, Yaakov , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | March 16, 2011 | Volume: 7 | Issue: 2 | Pages: 127-132

10.1016/j.jalz.2011.02.005 | PMID 21414553 Get It

The fourth Leon Thal Symposium (LTS2010) was convened in Toulouse, France, on November 3, 2010. This symposium reviewed design parameters that are necessary to develop comprehensive national databases on healthy aging. Such datasets offer the potential to serve as the foundation for a systems‐approach to solve the dual public health problems of: (1) early detection of people who are at elevated risk for Alzheimer's disease, and (2) the development of interventions to delay onset of, or prevent, late‐life dementia. The symposium considered three interrelated components of a National Database for Longitudinal Studies on Healthy Aging as follows: (a) a registry of healthy aging adults; (b) refined computer‐based assessments for data gathering, including assessments of behavioral/memory changes associated with aging that are appropriate for broad use in nonexpert settings; and (c) high performance computing/supercomputer‐based approaches for health data modeling and mining.
Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia
Steensma, David P. , Sloan, Jeff A. , Dakhil, Shaker R. , Dalton, Robert J., Kahanic, Stephen P., Prager, Diane J., Stella, Philip J., Rowland, Kendrith M. , Novotny, Paul J. , Loprinzi, Charles L. , Steensma, David P

Mayo Clinic

Journal of Clinical Oncology | November 23, 2010 | Volume: 29 | Issue: 1 | Pages: 97-105

10.1200/jco.2010.30.3644 | PMID 21098317 Get It

Purpose Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA. Patients and Methods This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received darbepoetin alfa once every 3 weeks and were randomly assigned to receive either ferric gluconate 187.5 mg intravenously (IV) every 3 weeks, oral daily ferrous sulfate 325 mg, or oral placebo for 16 weeks. Results There was no difference in the erythropoietic response rate (ie, proportion of patients achieving Hb ≥12 g/dL or Hb increase ≥ 2 g/dL from baseline): 69.5% (95% CI, 61.9% to 76.5%) of IV iron-treated patients achieved an erythropoietic response compared with 66.9% (95% CI, 59.1% to 74.0%) who received oral iron and 65.0% (95% CI, 57.2% to 72.3%) who received oral placebo (P = .75). There were also no differences in the proportion of patients requiring red cell transfusions, changes in quality of life, or the dose of darbepoetin administered. Adverse events (AEs) tended to be more common in the IV iron arm: grade 3 or higher AEs occurred in 54% (95% CI, 46% to 61%) of patients receiving IV iron compared with 44% (95% CI, 36% to 52%) who received oral iron and 46% (95% CI, 38% to 54%) who received oral placebo (P = .16). Conclusion In patients with CAA, addition of IV ferric gluconate to darbepoetin failed to provide additional benefit compared with oral iron or oral placebo.
High normal fasting blood glucose is associated with dementia in Chinese elderly
Mortimer, James A., Borenstein, Amy R., Ding, Ding , DeCarli, Charles , Copenhaver, Cathleen, Guo, Qihao , Chu, Shugang, Salmon, David P. , Wu, Yougui , Petersen, Ronald C. , Hong, Zhen , Zhao, Qianhua , Galasko, Douglas , Dai, Qi , DeCarli, Charles

Mayo Clinic

Alzheimer's & Dementia | November 1, 2010 | Volume: 6 | Issue: 6 | Pages: 440-447

10.1016/j.jalz.2010.03.017 | PMID 21044774 Get It

BackgroundDiabetes is a risk factor for mild cognitive impairment (MCI) and dementia. However, the association between high normal fasting blood glucose (FBG) and dementia has not been studied.MethodsPolytomous logistic regression was used to assess the association of dementia and MCI with FBG in an age‐ and sex‐matched sample of 32 dementia patients, 27 amnestic MCI (aMCI) patients, and 31 normal controls (NC). Analyses were repeated for those with normal FBG. Correlations between FBG and cognitive test scores were obtained.ResultsControlling for age, gender, education, body mass index, Hachinski Ischemic Score, magnetic resonance imaging (MRI) stroke, and normalized brain, hippocampal, and white matter hyperintensity MRI volumes; higher FBG was associated with dementia versus aMCI status (OR = 3.13; 95% CI, 1.28–7.69). This association remained (OR = 7.75; 95% CI, 1.10–55.56) when analyses were restricted to subjects with normal FBG. When dementia patients were compared with NC adjusting for age, gender, and education, a significant association with FBG also was seen (OR = 1.83; 95% CI, 1.09–3.08), but it was lost when vascular covariates were added to the model. FBG was not associated with aMCI status versus NC. Higher FBG was correlated with poorer performance on the Trailmaking Test Part B (P = .003). The percentage of dementia patients with high normal FBG (90%) was significantly higher than that of aMCI patients with high normal FBG (32.9%) (χ2 = 13.9, P < .001).ConclusionsHigher FBG was associated with dementia (vs. aMCI) independent of vascular risk factors and MRI indicators of vascular disease, and remained a significant risk factor when analyses were restricted to subjects with normal FBG. The results of this cross‐sectional study suggest that a high normal level of FBG may be a risk factor for dementia.